Identification of a novel negative allosteric modulator of the D3 dopamine receptor

被引：0
|
作者：
Moritz, Amy E. [1 ]
Free, R. Benjamin [1 ]
Conroy, Jennie L. [1 ]
Barnaeva, Elena S. [2 ]
Hu, Xin [2 ]
Javitch, Jonathan A. [3 ]
Southall, Noel T. [2 ]
Ferrer, Marc [2 ]
Frankowski, Kevin J. [4 ]
Aube, Jeffrey [4 ]
Sibley, David R. [1 ]
机构：
[1] NINDS, Mol Neuropharmacol Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
[2] NIH, Natl Ctr Adv Translat Sci, Rockville, MD USA
[3] Columbia Univ, Dept Psychiat, New York, NY USA
[4] Univ N Carolina, Chapel Hill, NC USA
来源：
FASEB JOURNAL | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
931.11
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation
    Maggio, Roberto
    Scarselli, Marco
    Capannolo, Marta
    Milian, Mark J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (09) : 1470 - 1479
  • [32] Identification and pharmacological characterization of a novel β-arrestin-biased negative allosteric modulator of the β
    De Pascali, Francesco F.
    Ippolito, Michael
    Hopfinger, Nathan
    Komolov, Konstantin E.
    Laurinavichyute, Daniela K.
    Sakkal, Leon A.
    Nayak, Ajay P.
    Reddy, Poli A. N.
    Donover, Preston S.
    Reichman, Melvin
    Salvino, Joseph M.
    Penn, Raymond B.
    Armen, Roger S.
    Scott, Charles P.
    Benovic, Jeffrey L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [33] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90
  • [34] ASSOCIATION BETWEEN DOPAMINE D3 RECEPTOR GENOTYPE AND RESPONSE TO A DOPAMINE D3 RECEPTOR ANTAGONIST IN SCHIZOPHRENIC SUBJECTS.
    Bhathena, A.
    Wang, Y.
    Kraft, J. B.
    Idler, K. B.
    Abel, S. J.
    Holley-Shanks, R. R.
    Robieson, W. Z.
    Spear, B. B.
    Redden, L.
    Katz, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S76 - S76
  • [35] Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor
    Wood, MD
    Boyfield, I
    Nash, DJ
    Jewitt, FR
    Avenell, KY
    Riley, GJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 407 (1-2) : 47 - 51
  • [36] Dopamine D3 receptor polymorphism associated with amisulpride response on negative symptoms of schizophrenia
    Huang, S. Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S426 - S426
  • [37] Fused aminotetralins:: Novel antagonists with high selectivity for the dopamine D3 receptor
    Avenell, KY
    Boyfield, I
    Coldwell, MC
    Hadley, MS
    Healy, MAM
    Jeffrey, PM
    Johnson, CN
    Nash, DJ
    Riley, GJ
    Scott, EE
    Smith, SA
    Stacey, R
    Stemp, G
    Thewlis, KM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (20) : 2859 - 2864
  • [38] Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists
    Micheli, Fabrizio
    Cremonesi, Susanna
    Semeraro, Teresa
    Tarsi, Luca
    Tomelleri, Silvia
    Cavanni, Paolo
    Oliosi, Beatrice
    Perdona, Elisabetta
    Sava, Anna
    Zonzini, Laura
    Feriani, Aldo
    Braggio, Simone
    Heidbreder, Christian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (04) : 1329 - 1332
  • [39] Novel selective dopamine D3 receptor modulators for the treatment of cocaine addiction
    Chen, Peng-Jen
    Blass, Benjamin
    Gordon, John
    Luedtke, Robert
    Taylor, Michelle
    Korzekwa, Kenneth
    Ye, Min
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [40] A new twist to novel atypical antipsychotics:: Dopamine D3 receptor antagonism
    Drescher, K. U.
    Freeman, A. S.
    Wicke, K. M.
    Unger, L. V.
    Wernet, W.
    Haupt, A.
    Gross, G.
    Decker, M. W. .
    Schoemaker, H.
    Sullivan, J. P.
    BEHAVIOURAL PHARMACOLOGY, 2007, 18 : S4 - S4
12345